Home » News and events » Press releases

Press releases

Press releases

  • June 4, 2019

    BioMed Propulsion Program: Québec grants $ 4 million loan to Alethia Biotherapeutics

    Through the BioMed Propulsion program, administered by Investissement Québec, the MEI is providing a $ 4 million loan to Alethia Biotherapeutics to support the completion of a project valued at $ 17 million. The BioMed Propulsion program improves access to financing for companies in the life sciences sector.

    Alethia will conduct a phase II clinical trial of AB-16B5, a therapeutic antibody for the treatment of metastatic non-small cell lung cancer (NSCLC). The funding will also support research on another biological product of the company.

    Québec intends to position itself in the promising sector of biological products, as confirmed in the Quebec Strategy for Life Sciences. Support to Alethia helps strengthen this growing sector.

  • May 21, 2015

    MONTREAL, May 21, 2015 – Alethia Biotherapeutics Inc. announced today the commencement of patient dosing in a Phase 1 clinical trial with AB-16B5, a fully humanized monoclonal antibody that inhibits epithelial to mesenchymal transition (EMT), in patients with advanced solid tumors.

     

  • February 17, 2015

    Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers

    Alethia PR 150217_EN

  • January 20, 2015

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,937,163 entitled “Antibodies against kidney associated antigen 1 and antigen binding fragments thereof” by the United States Patent and Trademark Office (“USPTO”)

  • December 2, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,900,579 entitled “Siglec-15 antibodies in treating bone loss-related diseases” by the United States Patent and Trademark Office (“USPTO”)

  • August 12, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,802,826  entitled “Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume” by the United States Patent and Trademark Office (“USPTO”)

  • August 1, 2014

    Alethia Biotherapeutics announces the issuance of patent JP5589149  entitled “Polynucleotides and polypeptide sequences involved in cancer ” by the Japan Patent Office

  • June 20, 2014

    Alethia Biotherapeutics announces the issuance of patent JP5564249 entitled “Polynucleotides and polypeptide sequences involved in cancer ” by the Japan Patent Office

  • June 3, 2014

    Alethia Biotherapeutics announces the issuance of U.S. Patent No. 8,741,289  entitled “Siglec-15 antibodies in treating bone loss-related diseases” by the United States Patent and Trademark Office (“USPTO”)

  • March 5, 2014

    Alethia Biotherapeutics announces the issuance of patent EP2275547 entitled “Polynucleotides and polypeptide sequences involved in the process of bone remodeling ” by the European Patent Office